Ajinomoto Co., Ltd.

Hisayuki Uneyama

Kunio Torii

Tomoyuki Onishi

Seiji Niwa

Takami Maekawa

Tatsuro Tanaka

Ana San Gabriel

Naoki Hayashi

Itaru Kon

Shinji Somekawa

Kiyoshi Miwa

Morikazu Kito

Akira Takahara

Yukitsugu Ono

Shinichi Fujita

Seiji Ohno

Hitoo Nishino

Cesario V Borlongan

The present invention relates to a nutrient composition which contains at least a carbohydrate, a lipid, a protein, and a mineral, and is liquid or semisolid, characterized in that the volume-based median size (d50) of particles in the nutrient composition is 5 to 100 &#x3bc;m and water-insoluble particles having a protein insolubilized by a divalent cation are contained as a major component of the nutrient composition, or a nutrient composition which contains at least a carbohydrate, a lipid, a protein, and a mineral, and is liquid or semisolid, characterized in that water-insoluble particles having a protein insolubilized by a divalent cation are contained as a major component of the nutrient composition and the mass of the protein with respect to the total moles of divalent ions forming the water-insoluble particles is 1.5 to 3 g/mmol.

Nutrient composition

As a nutritional composition and a composition for the prophylaxis or improvement of lower gastrointestinal function, which improve lower gastrointestinal function and are effective for the prophylaxis or improvement of diarrhea, gastroesophageal reflux or misswallowing caused by administration of a liquid nutritional supplement, the present invention provides a nutritional composition and a composition for the prophylaxis or improvement of lower gastrointestinal function, which comprise at least one kind selected from glutamic acid, 5'-nucleotide and a salt thereof, wherein, when glutamic acid alone is contained, the content thereof on administration is 0.0013-1.3 w/v % as free glutamic acid.

Nutrient composition and composition for prevention/mitigation of digestive tract depression

An isolated DNA molecule which encodes a novel glutamate receptor and a transformed cell expressing the receptor are provided.

Glutamate receptors and utilization thereof

The inventive subject matter relates to a glutamate receptor, DNA which encodes the receptor, a transformed cell expressing the receptor, a method for producing the receptor, a method for identifying an agonist, antagonist, or allosteric modulator for glutamic acid, a method for identifying an agonist for glutamic acid, an antibody to the receptor, and processes for making glutamate receptor modulators and pharmaceutical compositions comprising said modulator.

Glutamate receptor and utilization thereof

An agonist or antagonist of glutamic acid or an allosteric modulator is screened by reacting a glutamic acid receptor protein having the following properties with a substance binding thereto in the presence of a test substance and detecting the inhibition or promotion of the reaction: (A) it has a transmembrane domain and an intracellular domain common to those of type 4 metabotropic glutamic acid receptor protein, or (B) it has an extracellular domain by about 316 or 327 amino acid residues shorter than that of the type 4 metabotropic glutamic acid receptor protein.

Glutamic acid receptor and utilization thereof

Dihydropyridine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel. They are used as remedies for various diseases relating to the N-type calcium channel such as encephalopathies caused by the ischemia in the acute phase after the onset of cerebral infarction, cerebral hemorrhage or the like, Alzheimer's disease, etc.

Dihydropyridine derivative

Dihydropyridine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel. They are used as remedies for various diseases relating to the N-type calcium channel.

The administration of a therapeutically effective amount of melatonin is an effective method for treating paralysis of the extremities caused by cerebral infarction.

Growing community of inventors

Kawasaki, Japan

Hisayuki Uneyama